Alogliptin-Associated Angioedema: Case Report and Review of the Literature

Am J Ther. 2022 Nov-Dec;29(6):e748-e749. doi: 10.1097/MJT.0000000000001214. Epub 2020 Aug 3.

Authors

Ahmed Yeddi¹, Muhammad Abdelhai¹, Abu-Bekr Mohamed¹, Omer Yeddi², Lubna Salih³, Mohammed Ali¹, Mohammed Yeddi⁴

Affiliations

¹ Department of Internal Medicine, Wayne State University/Detroit Medical Center, Detroit, MI.
² Department of Toxicology, Omudrman Islamic University, Khartoum, Sudan.
³ Department of Internal Medicine, Faculty of Medicine, University of Khartoum, Khartoum, Sudan.
⁴ Department of Internal Medicine, Rashid Hospital, Dubai, United Arab Emirates.

PMID: 32769388
DOI: 10.1097/MJT.0000000000001214

No abstract available

Publication types

Review
Case Reports
Letter

MeSH terms

Angioedema* / chemically induced
Angioedema* / diagnosis
Blood Glucose
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Dipeptidyl-Peptidase IV Inhibitors* / adverse effects
Humans
Hypoglycemic Agents
Piperidines / adverse effects
Uracil / adverse effects

Substances

alogliptin
Piperidines
Uracil
Hypoglycemic Agents
Dipeptidyl-Peptidase IV Inhibitors
Blood Glucose